Overview
Portfolio 3
| Date | Name | Website | Total Raised | Location |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Sep 10, 2025 | PsiQuantum | psiquantum.com | $2.82B | United States |
| Aug 11, 2025 | Equillium | equilliumbio.com | $50M | United States, California, San Diego |
Mentions in press and media 23
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 9, 2026 | Expedition Therapeutics Lands $115M Series B | SAN FRANCISCO, CA, Expedition Therapeutics has announced the closing of an oversubscribed $115 million Series B financing round. >> Click here for more funding data on Expedition Therapeutics >> To export Expedition Therapeutic... |
| Aug 5, 2026 | Expedition Therapeutics Raises $115M in Series B Funding | Expedition Therapeutics, a San Francisco, CA-based clinical-stage biotechnology platform, raised $115M in Series B financing. The round was led by General Atlantic with participation from RA Capital, Vivo Capital, Sofinnova Investments, Nov... |
| Aug 3, 2026 | Claris Biotherapeutics Raises $118M in Series B Funding | Claris Biotherapeutics, Inc., a Jersey City, NJ-based biopharmaceutical company developing therapies for sight-threatening conditions, raised $118M in Series B financing. The round was led by Samsara Biocapital and Catalio Capital Managemen... |
| Jun 29, 2026 | Lycia Therapeutics Raises $75 Million Series D To Advance LYTAC Pipeline | Lycia Therapeutics announced that it has completed an oversubscribed $75 million Series D financing. The financing was co-led by existing investor Janus Henderson Investors and new investor Balyasny Asset Management. The round also included... |
| Jun 29, 2026 | Lycia Therapeutics Raises $75M in Series D Funding | Lycia Therapeutics, a South San Francisco, California-based developer of extracellular protein degradation and lysosomal targeting chimera (LYTAC) therapeutics, raised $75m in Series D funding. The round was co-led by Janus Henderson Invest... |
| Oct 10, 2025 | Expedition Therapeutics Raises $165M in Funding | Expedition Therapeutics, a San Francisco, CA-based biotech company developing therapies for novel inflammatory and respiratory diseases, raised $165M in Series A financing. The round was led by Sofinnova Investments and Novo Holdings, with ... |
| Oct 9, 2025 | Expedition resupplies for phase 2 COPD voyage with $165M series A | Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a study in patients with chronic obstruct... |
| Oct 9, 2025 | Expedition Therapeutics: $165 Million Series A Raised For Advancing DPP1 Inhibitor For COPD | Expedition Therapeutics, a biotechnology company dedicated to developing therapies for novel inflammatory and respiratory diseases, has closed an oversubscribed and upsized Series A financing round, raising $165 million. This financing roun... |
| Sep 10, 2025 | Quantum Leap: PsiQuantum Secures $1 Billion, Partners With Nvidia | PsiQuantum, a leader in quantum computing, just secured $1 billion in Series E funding. This propels its valuation to $7 billion. A pivotal partnership with Nvidia was also announced. This collaboration accelerates the development of PsiQua... |
Reviews 0
FAQ about Adage Capital Management
How many startups has Adage Capital Management invested in?
Adage Capital Management has 3 portfolio companies on Parsers VC, among them PsiQuantum and Equillium.
What has the press written about Adage Capital Management?
Parsers VC has collected 23 articles mentioning Adage Capital Management, among them “Expedition Therapeutics Lands $115M Series B” (Aug 9, 2026) and “Expedition Therapeutics Raises $115M in Series B Funding” (Aug 5, 2026).
Is Adage Capital Management still active?
Yes, Adage Capital Management is active; its latest activity on Parsers VC dates from Aug 10, 2026.